Edaravone for prevention of contrast induced acute kidney injury (CI-AKI)

Abstract

Contrast-induced nephropathy (CI-AKI) is a rapid decline in renal function several days after intravascular exposure. Edaravone (EDA) as a potent free radical inhibitor improves oxidative stress. This study was designed and conducted with the aim of investigating the effect of EDA for the prevention of acute kidney injury caused by contrast nephropathy. Materials & methods. In this randomized clinical trial study, patients of Shahid Madani Hospital requiring coronary artery angiography were selected and divided into two groups of 45 people. EDA drug was injected into the intervention group in the form of a solution one hour before angiography with a dose of 60 mg within 60 minutes. Clinical results were examined, compared and analyzed 5 days after the intervention. Results. Clinical findings showed that 10 % patients were elective, 25.6% had unstable angina, 25.6% were NSTEMI and 38.9% were STEMI, and their distribution was statistically different between the two groups (P<0.001). In addition, it was found that five of the total patients were diagnosed with AKI during this period and EDA has no role on its incidence (P=0.361).